Creation of a long-acting nanoformulated dolutegravir

Brady Sillman; Aditya N. Bade; Prasanta K. Dash; Biju Bhargavan; Ted Kocher; Saumi Mathews; Hang Su; Georgette D. Kanmogne; Larisa Y. Poluektova; Santhi Gorantla; JoEllyn McMillan; Nagsen Gautam; Yazen Alnouti; Benson Edagwa; Howard E. Gendelman

doi:10.1038/s41467-018-02885-x

Nature Communications (Feb 2018)

Creation of a long-acting nanoformulated dolutegravir

Brady Sillman,
Aditya N. Bade,
Prasanta K. Dash,
Biju Bhargavan,
Ted Kocher,
Saumi Mathews,
Hang Su,
Georgette D. Kanmogne,
Larisa Y. Poluektova,
Santhi Gorantla,
JoEllyn McMillan,
Nagsen Gautam,
Yazen Alnouti,
Benson Edagwa,
Howard E. Gendelman

Affiliations

Brady Sillman: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Aditya N. Bade: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Prasanta K. Dash: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Biju Bhargavan: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Ted Kocher: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Saumi Mathews: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Hang Su: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Georgette D. Kanmogne: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Larisa Y. Poluektova: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Santhi Gorantla: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
JoEllyn McMillan: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Nagsen Gautam: Department of Pharmaceutical Sciences, University of Nebraska Medical Center
Yazen Alnouti: Department of Pharmaceutical Sciences, University of Nebraska Medical Center
Benson Edagwa: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
Howard E. Gendelman: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center

DOI: https://doi.org/10.1038/s41467-018-02885-x
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 14

Abstract

Read online

Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal